On June 30, 2022, PMPRB issued a Notice and Comment which published its Proposed Interim Guidance and invited stakeholder comments until July 18, 2022.
This Interim Guidance outlines PMPRB’s intentions for regulating the prices of patented medicines in the “interim period” between the coming-into-force date of the new regulations (July 1, 2022) and publication and implementation of a final set of guidelines.
PDCI strives to support timely transparency around public policy consultations and invites organizations and individuals who provided comments to PMPRB to share their submissions here so ideas may be openly shared among interested stakeholders. PDCI will post the consultation responses received here on PDCI’s website.
To participate, please e-mail Veronique Scott, Policy Manager, at email@example.com with a PDF version of your response including consent for PDCI to publish the response on its website.
Thank you to all stakeholders who share their responses.
Note: PMPRB intends to make the written submissions publicly available on its website after the closing of the consultation. However, timing for this is not yet clear. Once PMPRB publishes the comprehensive set of submissions, PDCI’s sharing page will direct visitors to the comprehensive set of submissions on the PMPRB website.